NGeneBio Co. Ltd.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myelopro… Read more
NGeneBio Co. Ltd. (354200) - Total Liabilities
Latest total liabilities as of September 2025: ₩28.13 Billion KRW
Based on the latest financial reports, NGeneBio Co. Ltd. (354200) has total liabilities worth ₩28.13 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NGeneBio Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how NGeneBio Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NGeneBio Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of NGeneBio Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Peña Verde S.A.B
MX:PV
|
Mexico | MX$39.01 Billion |
|
Matsa Resources Ltd
AU:MAT
|
Australia | AU$12.59 Million |
|
Shuang-Bang Industrial
TWO:6506
|
Taiwan | NT$1.25 Billion |
|
Gediz Ambalaj Sanayi ve Ticaret AS
IS:GEDZA
|
Turkey | TL223.98 Million |
|
Indonesia Fibreboard Industry PT
JK:IFII
|
Indonesia | Rp402.69 Billion |
|
Ninety One Ltd
JSE:NY1
|
South Africa | ZAC13.25 Billion |
|
Dongsin Engineering & Construction
KQ:025950
|
Korea | ₩11.39 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down NGeneBio Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NGeneBio Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NGeneBio Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of NGeneBio Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.97 Billion | -38.68% |
| 2023-12-31 | ₩26.05 Billion | -15.61% |
| 2022-12-31 | ₩30.87 Billion | +212.76% |
| 2021-12-31 | ₩9.87 Billion | +24.23% |
| 2020-12-31 | ₩7.94 Billion | -19.40% |
| 2019-12-31 | ₩9.86 Billion | -28.97% |
| 2018-12-31 | ₩13.88 Billion | -- |